Oncolytics Biotech Discloses American Society of Clinical Oncology Annual Meeting Abstracts, Highlights Pelareorep's Potential In Pancreatic Cancer And Immunotherapeutic Mechanism Of Action
Oncolytics Biotech Discloses American Society of Clinical Oncology Annual Meeting Abstracts, Highlights Pelareorep's Potential In Pancreatic Cancer And Immunotherapeutic Mechanism Of Action
One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The second describes pelareorep's ability to induce the expansion of tumor-infiltrating lymphocytes (TILs) across multiple cancers and the correlation between TIL expansion and tumor response. The ASCO annual meeting will take place from May 31 – June 4, 2024, in Chicago, Illinois.
其中一份是正在进行的试验摘要，讨论了GOBLET研究的第5组，该研究将评估在新诊断的转移性胰腺导管腺癌（PDAC）患者中使用pelareorep和改性FOLFIRINOX（mfolfirinox）与阿替珠单抗和不含阿替唑单抗的组合。第二部分描述了pelareorep在多种癌症中诱导肿瘤浸润淋巴细胞（TIL）扩张的能力以及TIL扩张与肿瘤反应之间的相关性。ASCO 年会将于 2024 年 5 月 31 日至 6 月 4 日在伊利诺伊州芝加哥举行。